# OnCo record tub-040 (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/tub-040/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "tub-040" ;
  schema:name "TUB-040"@en ;
  schema:description "TUB-040 is an experimental antibody-drug conjugate from Tubulis (Gilead), in phase 2 trials for platinum-resistant ovarian cancer, non-small cell lung cancer and endometrial cancer."@en ;
  schema:url <https://onco.cc/drugs/tub-040/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://tubulis.com/our-pipeline/>, <https://tubulis.com/our-pipeline/>, <https://tubulis.com/news/gilead-to-acquire-tubulis-adding-potentially-best-in-class-antibody-drug-conjugate-and-next-generation-platform-to-further-strengthen-oncology-pipeline/>, <https://clinicaltrials.gov/api/v2/studies/NCT07743541>, <https://clinicaltrials.gov/search?intr=TUB-040> ;
  onco:status "phase-2" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:modality "Antibody-drug conjugate" ;
  onco:cancers <https://onco.cc/cancers/platinum-resistant-ovarian-cancer/>, <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/endometrial/> ;
  onco:targets <https://onco.cc/targets/slc34a2/> ;
  onco:companies <https://onco.cc/companies/tubulis/> ;
  onco:trials <https://onco.cc/trials/nct06303505/>, <https://onco.cc/trials/nct07736937/>, <https://onco.cc/trials/nct07743541/>, <https://onco.cc/trials/nct07806773/> .